DGIdb - IPILIMUMAB Drug Record

IPILIMUMAB chembl:CHEMBL1789844 ApprovedAntineoplastic

Alternate Names:

YERVOY
IPILIMUMAB
MDX-101
BMS-734016
MDX-010
MDX-CTLA-4
MOAB-CTLA-4
drugbank:06186
chembl:CHEMBL1789844
chemidplus:477202-00-9
rxcui:1094833

Drug Info:

FDA Approval	Melanoma
Drug Class	Therapeutic Antibodies
FDA Approval	approved
Drug Class	monoclonal antibody
Drug Indications	antineoplastic agent
Pharmaceutical Developer	Bristol-Myers Squibb
Source Reported Drug Name(s)	Yervoy/ipilimumab
Drug Categories	adjuvants, immunologic
Drug Categories	antibodies, monoclonal, humanized
Drug Categories	antineoplastic agents, immunological
Drug Categories	ctla-4-directed antibody interactions
Drug Categories	ctla-4-directed blocking antibody
Drug Categories	drugs that are mainly renally excreted
Drug Categories	immunoglobulin g
Drug Categories	increased t lymphocyte activation
Drug Categories	narrow therapeutic index drugs

(9 More Sources)

Publications:

Yang et al., Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis., J. Immunother.
Tsao SC et al., 2015, Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations., Sci Rep
Miao D et al., 2018, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma., Science
Kato et al., 2017, Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate., Clin. Cancer Res.

IPILIMUMAB CTLA4

Interaction Score: 6.31

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand Binding

Direct Interaction? True

PMIDs:
18049334

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions GuideToPharmacology CancerCommons TTD
IPILIMUMAB PBRM1

Interaction Score: 2.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29301960

Sources:
CIViC
IPILIMUMAB HLA-A

Interaction Score: 1.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
IPILIMUMAB MDM2

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28351930

Sources:
CIViC
IPILIMUMAB NRAS

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26095797

Sources:
CIViC

DrugBank: DB06186
- Version: 5.1.7
Alternate Names:

IPILIMUMAB DrugBank Drug Name

477202-00-9 CAS Number

Yervoy Drug Brand

Drug Info:

Drug Type biotech

Drug Groups approved

Drug Categories adjuvants, immunologic

Publications:

Yang et al., Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis., J. Immunother.
MyCancerGenome: IPILIMUMAB
- Version: 20-Jun-2017
Alternate Names:

MDX-010 Development Name

MDX-101 Development Name

BMS-734016 Development Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Melanoma

Publications:
CancerCommons: IPILIMUMAB
- Version: 25-July-2013
Alternate Names:

Yervoy Drug Trade Name

Ipilimumab Drug Development Name

Drug Info:

Drug Class Monoclonal Antibody

Source Reported Drug Name(s) Yervoy/ipilimumab

Pharmaceutical Developer Bristol-Myers Squibb

Publications:
TdgClinicalTrial: IPILIMUMAB
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval approved

Publications:

CIViC: IPILIMUMAB

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Tsao SC et al., 2015, Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations., Sci Rep

Kato et al., 2017, Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate., Clin. Cancer Res.

Miao D et al., 2018, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma., Science

TTD: Ipilimumab
- Version: 2020.06.01
Alternate Names:

D07BVI TTD Drug ID

Drug Info:

Publications:
TALC: IPILIMUMAB
- Version: 12-May-2016
Alternate Names:

IPILIMUMAB Primary Drug Name

IPILIMUMAB Drug Generic Name

YERVOY Drug Trade Name

Drug Info:

Publications:
GuideToPharmacology: 178103470
- Version: 29-September-2020
Alternate Names:

IPILIMUMAB GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblInteractions: CHEMBL1789844
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL1789844
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: IPILIMUMAB
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
PharmGKB: ipilimumab
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:
FDA: Ipilimumab
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Endogenous Drug?	False
Specific Action of the Ligand	Binding
Direct Interaction?	True

IPILIMUMAB	DrugBank Drug Name
477202-00-9	CAS Number
Yervoy	Drug Brand

Drug Type	biotech
Drug Groups	approved
Drug Categories	adjuvants, immunologic

MDX-010	Development Name
MDX-101	Development Name
BMS-734016	Development Name

IPILIMUMAB	Primary Drug Name
IPILIMUMAB	Drug Generic Name
YERVOY	Drug Trade Name

antibody (inhibitory)
inhibitor (inhibitory)

IPILIMUMAB Drug Record

IPILIMUMAB chembl:CHEMBL1789844 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

IPILIMUMAB CTLA4

Interaction Types & Directionality: antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Endogenous Drug? False Specific Action of the Ligand Binding Direct Interaction? True

PMIDs: 18049334

Sources: TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions GuideToPharmacology CancerCommons TTD

IPILIMUMAB PBRM1

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29301960

Sources: CIViC

IPILIMUMAB HLA-A

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

IPILIMUMAB MDM2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28351930

Sources: CIViC

IPILIMUMAB NRAS

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26095797

Sources: CIViC

DrugBank: DB06186

Alternate Names: IPILIMUMAB DrugBank Drug Name 477202-00-9 CAS Number Yervoy Drug Brand

Drug Info: Drug Type biotech Drug Groups approved Drug Categories adjuvants, immunologic

Publications: Yang et al., Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis., J. Immunother.

MyCancerGenome: IPILIMUMAB

Alternate Names: MDX-010 Development Name MDX-101 Development Name BMS-734016 Development Name

Drug Info: Drug Class Therapeutic Antibodies FDA Approval Melanoma

Publications:

CancerCommons: IPILIMUMAB

Alternate Names: Yervoy Drug Trade Name Ipilimumab Drug Development Name

Drug Info: Drug Class Monoclonal Antibody Source Reported Drug Name(s) Yervoy/ipilimumab Pharmaceutical Developer Bristol-Myers Squibb

Publications:

TdgClinicalTrial: IPILIMUMAB

Alternate Names:

Drug Info: Drug Indications antineoplastic agent Drug Class monoclonal antibody FDA Approval approved

Publications:

CIViC: IPILIMUMAB

Alternate Names:

Drug Info:

TTD: Ipilimumab

Alternate Names: D07BVI TTD Drug ID

Drug Info:

Publications:

TALC: IPILIMUMAB

Alternate Names: IPILIMUMAB Primary Drug Name IPILIMUMAB Drug Generic Name YERVOY Drug Trade Name

Drug Info:

Publications:

GuideToPharmacology: 178103470

Alternate Names: IPILIMUMAB GuideToPharmacology Ligand Name

Drug Info:

Publications:

ChemblInteractions: CHEMBL1789844

Alternate Names:

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL1789844

Alternate Names:

Drug Info:

Publications:

ClearityFoundationClinicalTrial: IPILIMUMAB

Alternate Names:

Drug Info:

Publications:

PharmGKB: ipilimumab

Alternate Names:

Drug Info:

Publications:

FDA: Ipilimumab

Alternate Names:

Drug Info:

Interaction Types & Directionality:

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand Binding

Direct Interaction? True

PMIDs:
18049334

Sources:
TALC DrugBank MyCancerGenome TdgClinicalTrial ClearityFoundationClinicalTrial ChemblInteractions GuideToPharmacology CancerCommons TTD

Interaction Types & Directionality:

n/a

PMIDs:
29301960

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
28351930

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
26095797

Sources:
CIViC

Alternate Names:

IPILIMUMAB DrugBank Drug Name

477202-00-9 CAS Number

Yervoy Drug Brand

Drug Info:

Drug Type biotech

Drug Groups approved

Drug Categories adjuvants, immunologic

Publications:

Yang et al., Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis., J. Immunother.

Alternate Names:

MDX-010 Development Name

MDX-101 Development Name

BMS-734016 Development Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Melanoma

Alternate Names:

Yervoy Drug Trade Name

Ipilimumab Drug Development Name

Drug Info:

Drug Class Monoclonal Antibody

Source Reported Drug Name(s) Yervoy/ipilimumab

Pharmaceutical Developer Bristol-Myers Squibb

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval approved

Alternate Names:

D07BVI TTD Drug ID

Alternate Names:

IPILIMUMAB Primary Drug Name

IPILIMUMAB Drug Generic Name

YERVOY Drug Trade Name

Alternate Names:

IPILIMUMAB GuideToPharmacology Ligand Name